Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

2.

Flinn

IW

,

van der Jagt

R

,

Kahl

B

, et al.

First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study

.

J Clin Oncol

.

2019

;

37

(

12

):

984

-

991

.

3.

Chiu

H

,

Trisal

P

,

Bjorklund

C

, et al.

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

.

Br J Haematol

.

2019

;

185

(

2

):

240

-

253

.

4.

Zucca

E

,

Rondeau

S

,

Vanazzi

A

, et al;

Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group

.

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

.

Blood

.

2019

;

134

(

4

):

353

-

362

.

5.

Fowler

NH

,

Davis

RE

,

Rawal

S

, et al.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

.

Lancet Oncol

.

2014

;

15

(

12

):

1311

-

1318

.

6.

Martin

P

,

Jung

SH

,

Pitcher

B

, et al.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

.

Ann Oncol

.

2017

;

28

(

11

):

2806

-

2812

.

7.

Morschhauser

F

,

Fowler

NH

,

Feugier

P

, et al;

RELEVANCE Trial Investigators

.

Rituximab plus lenalidomide in advanced untreated follicular lymphoma

.

N Engl J Med

.

2018

;

379

(

10

):

934

-

947

.

8.

Cheson

BD

,

Horning

SJ

,

Coiffier

B

, et al;

NCI Sponsored International Working Group

.

Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas [published correction appears in J Clin Oncol. 2000;18(11):2351]

.

J Clin Oncol

.

1999

;

17

(

4

):

1244

.

9.

Buske

C

,

Hoster

E

,

Dreyling

M

,

Hasford

J

,

Unterhalt

M

,

Hiddemann

W

.

The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome

.

Blood

.

2006

;

108

(

5

):

1504

-

1508

.

10.

Federico

M

,

Bellei

M

,

Marcheselli

L

, et al.

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project

.

J Clin Oncol

.

2009

;

27

(

27

):

4555

-

4562

.

11.

Bachy

E

,

Maurer

MJ

,

Habermann

TM

, et al.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

.

Blood

.

2018

;

132

(

1

):

49

-

58

.

12.

Cheson

BD

,

Fisher

RI

,

Barrington

SF

, et al;

United Kingdom National Cancer Research Institute

.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

.

J Clin Oncol

.

2014

;

32

(

27

):

3059

-

3068

.

13.

Tobin

JWD

,

Keane

C

,

Gunawardana

J

, et al.

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration

.

J Clin Oncol

.

2019

;

37

(

34

):

3300

-

3309

.

14.

Menter

T

,

Tzankov

A

,

Zucca

E

, et al.

Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy

.

Br J Haematol

.

2020

;

189

(

4

):

707

-

717

.

15.

Strati

P

,

Ahmed

MAA

,

Fowler

N

, et al.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

.

Haematologica

.

2020

;

105

(

7

):

1907

-

1913

.

16.

Strati

P

,

Ahmed

MA

,

Nastoupil

LJ

, et al.

Pretreatment SUV_max may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

.

Leuk Lymphoma

.

2020

;

61

(

6

):

1380

-

1387

.

17.

Salles

G

,

Seymour

JF

,

Offner

F

, et al.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

.

Lancet

.

2011

;

377

(

9759

):

42

-

51

.

18.

Luminari

S

,

Biasoli

I

,

Versari

A

, et al.

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

.

Ann Oncol

.

2014

;

25

(

2

):

442

-

447

.

19.

Trotman

J

,

Fournier

M

,

Lamy

T

, et al.

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

.

J Clin Oncol

.

2011

;

29

(

23

):

3194

-

3200

.

20.

Dupuis

J

,

Berriolo-Riedinger

A

,

Julian

A

, et al.

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS

.

J Clin Oncol

.

2012

;

30

(

35

):

4317

-

4322

.

21.

Sargent

DJ

,

Shi

Q

,

Bedout

SD

, et al.

Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts)

.

J Clin Oncol

.

2015

;

33

(

suppl 15

):

8504

.

22.

Nastoupil

LJ

,

Westin

JR

,

Hagemeister

FB

, et al.

Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL) [abstract]

.

Blood

.

2019

;

134

(

suppl 1

). Abstract 125.

23.

Nastoupil

LJ

,

Lee

HJ

,

Hagemeister

FB

, et al.

Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: an open label, phase II study [abstract]

.

Blood

.

2018

;

132

(

suppl 1

). Abstract

447

.

24.

Davids

MS

,

Roberts

AW

,

Seymour

JF

, et al.

Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma

.

J Clin Oncol

.

2017

;

35

(

8

):

826

-

833

.

25.

Italiano

A

,

Soria

JC

,

Toulmonde

M

, et al.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

.

Lancet Oncol

.

2018

;

19

(

5

):

649

-

659

.

26.

Morschhauser

F

,

Tilly

H

,

Chaidos

A

, et al.

Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma [abstract]

.

Blood

.

2019

;

134

(

suppl 1

). Abstract

123

.

27.

Caruso

V

,

Di Castelnuovo

A

,

Meschengieser

S

, et al.

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events

.

Blood

.

2010

;

115

(

26

):

5322

-

5328

.

28.

Morton

LM

,

Curtis

RE

,

Linet

MS

, et al.

Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype

.

J Clin Oncol

.

2010

;

28

(

33

):

4935

-

4944

.

29.

Sarkozy

C

,

Maurer

MJ

,

Link

BK

, et al.

Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US Cohorts

.

J Clin Oncol

.

2019

;

37

(

2

):

144

-

152

.